BioMedican
Growth Stage
Producing pharmaceutical-grade cannabinoids at 70-90% lower cost via biosynthesis
Overview
Raised: $220,467
Total Commitments ($USD)
Platform
Wefunder
Start Date
08/12/2021
Close Date
10/02/2021
Min. Goal
$200,000
Max. Goal
$1,069,999
Min. Investment
$250
Security Type
Equity - Preferred
Series
Seed
SEC Filing Type
RegCF
Price Per Share
$4.50
Early Bird Valuation
$50,124,520
Pre-Money Valuation
$56,390,085
Rolling Commitments ($USD)
Status
Funded
Reporting Date
10/30/2021
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$4,409
# of Investors
163
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
Low
Capital Intensity
High
BioMedican, with a valuation of $56.4 million, is raising funds on Wefunder. The company makes cannabinoids through the process of biosynthesis. The pharmaceutical-grade cannabinoids of BioMedican are bio-organic, non-GMO, and cost 70-90% less than the current wholesale price. The company has research partnerships with the Institute of Genetics Moscow, Imperial College UK, and Denmark Technical University. The current crowdfunding campaign has a minimum target of $200,000 and a maximum target of $1,069,999. The campaign proceeds will be used for starting a pilot-scale fermentation equipment, buying additional equipment, usage of analytical services, and operational expenses.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-1,646,200 |
$-971,290 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$19,099 |
$134,712 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$138,963 |
$222,406 |
|
Short-Term Debt |
$510,970 |
$167,073 |
|
Long-Term Debt |
$9,160 |
$318,396 |
|
Total Liabilities |
$520,130 |
$485,469 |
Financials as of: 08/12/2021
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.